New combo therapy for lung transplant patients shows promise in antibody clearance
NCT ID NCT03798860
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at 340 lung transplant patients who had donor-specific antibodies, which can cause organ rejection. They received a combination of immunoglobulin therapy, plasmapheresis, and rituximab. The goal was to see if the antibodies cleared and if the transplanted lungs survived longer without rejection.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DONOR-SPECIFIC ANTI-HUMAN LEUKOCYTE ANTIGEN(HLA) ANTIBODIES are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hannover Medical School, Department of Cardiothoracic, Transplant and Vascular Surgery
Hanover, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can muscle strength predict lung transplant recovery?
- Blood markers may flag lung transplant danger — study investigates
- Your genes may hold the key to safer lung transplants
- Blood test clues could make antifungal dosing safer for transplant patients
- AI model could predict who needs a lung transplant for rare emphysema
- Could a simple supplement boost muscle strength before lung transplant?